Medical Developments International
Medical Developments International (MVP) is a pharmaceutical company focused on developing and distributing innovative medical devices. They operate in the acute pain and respiratory illness treatment sectors, aiming to improve patient care globally. MDI partners with organizations like CSIRO to drive industry-leading product development.
Short position
Medical Developments International (ASX:MVP) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 152 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 3.86% in September 2021. MVP is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Medical Developments International (MVP) short interest history
MVP Short Interest History
- 30-day change
- 0.00pp
- 90-day change
- 0.00pp
- 1-year change
- -0.00pp
- All-time high
- 3.86% (September 2021)
- All-time low
- 0.00% (December 2015)
Is MVP heavily shorted?
Not especially: 0.00% short interest is modest by ASX standards, ranking #732 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has MVP's short interest changed recently?
Over the past 30 days Medical Developments International's short interest has been broadly stable, and over 90 days it has been broadly stable. The current level is 0.00% of shares on issue.
What is the highest MVP's short interest has been?
Since 2013, Medical Developments International's short interest peaked at 3.86% in September 2021 and bottomed at 0.00% in December 2015.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2013. See our methodology.